Showing 2931-2940 of 3476 results for "".

• New Products

  https://practicaldermatology.com/columns/new-products/new-products/21167/
  • Text

• Can Vitamin B₃ Reduce Recurrence of NMSC?

  https://practicaldermatology.com/topics/practice-management/can-vitamin-b3-reduce-recurrence-of-nmsc/21165/
  A common OTC vitamin supplement shows early promise in preventing secondary NMSCs. Is it time to recommend it?
  • Text

• Who Do We Turn to Now?

  https://practicaldermatology.com/topics/practice-management/who-do-we-turn-to-now/21169/
  • Text

• Perform an SEO Audit for Your Website

  https://practicaldermatology.com/topics/practice-management/perform-an-seo-audit-for-your-website/21173/
  • Text

• Recent Developments

  https://practicaldermatology.com/columns/recent-developments/recent-developments/21171/
  • Text

• Managing Millennials

  https://practicaldermatology.com/topics/practice-management/managing-millennials/21188/
  How to provide guidance to these individuals as they adjust and adapt to today's workforce.
  • Text

• Advocacy Groups and Physicians: The New Power Couple

  https://practicaldermatology.com/topics/practice-management/advocacy-groups-and-physicians-the-new-power-couple/21191/
  Patient advocacy organizations partnering with dermatology physician-scientists offer an exciting new model for optimized patient care.
  • Text

• Currents

  https://practicaldermatology.com/topics/practice-management/currents/21190/
  Speak Up! Advocate for yourself, your patients, your specialty
  • Text

• Achieving Operational Success

  https://practicaldermatology.com/topics/practice-management/achieving-operational-success/21203/
  Document your practice systems to enhance the patient experience.
  • Text

• Pipeline Watch: Sizing Up a Promising Phase III IL-17 Biologic

  https://practicaldermatology.com/topics/psoriasis/pipeline-watch-sizing-up-a-promising-phase-iii-il-17-biologic/21214/
  Pipeline Watch is a new Q&A feature appearing periodically in Practical Dermatology® that explores the potential of therapeutic agents currently under investigation. In each edition, we will speak with investigators from manufacturing companies to gain insights about the development and investig
  • Text

• Previous
• 1
• 2
• …
• 292
• 293
• 294
• 295
• 296
• …
• 347
• 348
• Next